MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET

Company Participants

Zack Armen – Head-Investor Relations

Jennifer Buell – President and Chief Executive Officer

Marc Van Dijk – Chief Scientific Officer

Christine Klaskin – Principal Financial and Accounting Officer

Conference Call Participants

Emily Bodnar – H.C. Wainwright

Jack Allen – Baird

Matthew Phipps – William Blair

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the MiNK Therapeutics’ First Quarter 2023 Financial Results Call. I would now like to turn the call over to Zack Armen, Head of Investor Relations. Please go ahead.

Zack Armen

Thank you, operator, and thank you all for joining us today. Today’s call is being webcast and will be available on our website for replay. I’d like to remind you that this call will contain forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans as well as time lines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.

Joining me today on the call are Dr. Jennifer Buell, President and Chief Executive Officer; Dr. Marc Van Dijk, Chief Scientific Officer; Dr. Joy Zhou, Head of Manufacturing; and Christine Klaskin, Principal Financial and Accounting Officer.

Now I’d like to turn the call over to Dr. Buell to highlight our progress from the quarter.

Jennifer Buell

Thank you very much, Zack. Good morning, and thank you for joining our first quarter 2023 earnings call. We’re very happy to be here with you and to present on an exciting first quarter, which actually culminates in a significant presentation at the American Association of Cancer Research Conference or the AACR conference just a couple of weeks ago.

Dr. Benny Carneiro, a medical oncologist and associate professor at Brown University Oncology presented data on our Phase I study. He reported first pivot kind clinical benefit of an allogeneic or off-the-shelf iNKT therapy in patients with solid tumor cancers. Dr. Carneiro specifically highlighted clinical responses and biomarker responses in patients who have failed all available therapies, including anti-PD-1 therapy. We observed these responses in patients with metastatic gastric cancer, non-small cell lung cancer, testicular cancer and long-term disease stabilization in a number of other solid tumor cancers.

These data underscore what we believe to be the most flexible and impactful cell therapy in development. MiNK remains at the forefront of this technology advancing iNKTs in the clinic as we’re advancing this not only in the clinic as well as in our manufacturing suites, but also we’re advancing a very robust pipeline of novel therapies that Dr. Marc Van Dijk will share with you shortly.